Look back at pharma news in the week to November 20, 2020

22 November 2020

By Barbara Obstoj-Cardwell. Editor

Clinical trial results featured in last week’s news, some good and others not so good. Cytokinetics and Amgen presented mixed Phase III data on their omecamtiv mecarbil in heart failure. Meantime, US biotech Moderna created another wave of COVID-19 euphoria, releasing strong new data on its vaccine candidate mRNA-1273. But there was a major disappointment for BrainStorm Cell Therapeutics with the Phase III study of its amyotrophic lateral sclerosis (ALS) candidate NurOwn. Elsewhere, questions were raised about the price being paid for the remaining shares in Urovant, and its over-active bladder (OAB) lead candidate vibregon, by Sumitovant Biopharma, a unit of Japan’s Sumitomo Dainippon.

Difficult path ahead for omecamtiv via subgroup data

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK